BTTC08-01: A phase II study of bevacizumab and erlotinib after radiation therapy and temozolomide in patients with newly diagnosed glioblastoma (GBM) without MGMT promoter methylation.
Jeffrey J. Raizer
Consultant or Advisory Role - Genentech
Honoraria - Genentech
Research Funding - Genentech
Pierre Giglio
No relevant relationships to disclose
Jethro Lisien Hu
No relevant relationships to disclose
Morris D. Groves
Consultant or Advisory Role - Genentech
Research Funding - Genentech
Ryan Merrell
No relevant relationships to disclose
Charles A. Conrad
No relevant relationships to disclose
Surasak Phuphanich
No relevant relationships to disclose
Vinay K. Puduvalli
Consultant or Advisory Role - Genentech; Novartis
Honoraria - Genentech; Novartis
Research Funding - Celgene; Genentech; Merck; Pfizer
Monica Elena Loghin
No relevant relationships to disclose
Nina Paleologos
Consultant or Advisory Role - Eisai; Genentech
Honoraria - Genentech; Merck
W. K. Alfred Yung
Consultant or Advisory Role - Actelion; Merck; Novartis
Honoraria - Actelion; Merck; Novartis
Research Funding - Daiichi Sankyo; Novartis
Brian D. Vaillant
No relevant relationships to disclose
Jeremy David Rudnick
No relevant relationships to disclose
Marc C. Chamberlain
No relevant relationships to disclose
Nicholas Vick
No relevant relationships to disclose
Sean Aaron Grimm
Consultant or Advisory Role - Genentech
Research Funding - Genentech
Ivo Tremont-Lukats
No relevant relationships to disclose
John Frederick De Groot
Consultant or Advisory Role - Genentech; VBL Therapeutics
Honoraria - Merck
Research Funding - AstraZeneca; EMD Serono; Sanofi
Kenneth D. Aldape
No relevant relationships to disclose
Mark R. Gilbert
Consultant or Advisory Role - EMD Serono; Genentech; Merck; Novartis
Honoraria - EMD Serono; Genentech (I); Merck; Novartis
Research Funding - Genentech; GlaxoSmithKline; Merck